RT Journal Article
SR Electronic
T1 Comparative study between first and second wave of COVID-19 deaths in India - a single center study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.05.09.22274860
DO 10.1101/2022.05.09.22274860
A1 Prakash Tendulkar
A1 Pragya Pandey
A1 Prasan Kumar Panda
A1 Ajeet Singh Bhadoria
A1 Poorvi Kulshreshtha
A1 Mayank Mishra
A1 Gaurika Saxena
YR 2022
UL http://medrxiv.org/content/early/2022/05/10/2022.05.09.22274860.abstract
AB Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuously evolving and many mutant variants of the virus are circulating in the world. Recurrent waves of COVID-19 have caused enormous mortality all over the world. It is of utmost importance for a health expert to understand the demographic and clinical attributes between the first and second waves of COVID-19 induced deaths.Method This was a hospital record based comparative study of baseline demographic, clinical and laboratory parameters of the first and second wave of COVID-19 in a tertiary care hospital in Uttarakhand, India. The study included all deceased patients admitted to the hospital during the first and second wave of COVID-19, i.e., between March 2020 to January 2021 and between March 2021 to June 2021, respectively.Result The study showed that there were more casualties in the second wave compared to the first, 475 (19.8%) and 424 (24.1%) respectively. There was no significant difference in terms of age. A male preponderance of mortality was evident in both the waves. The median duration of hospital stay was 5 (3-10) days in the second wave, which is significantly different from the corresponding duration in first wave (p<o.ooo). The most common clinical manifestation among the deceased were dyspnoea in both the waves, followed by fever and cough, the difference was statistically significant for cough (p< 0.000) The most prevalent comorbidity was diabetes mellitus (DM), followed by hypertension (HTN), with significant difference for HTN (p<0.003). The most frequently deranged lab parameter was lymphopenia with a significant difference across both the waves (p<0.000).Conclusion In both the first and second COVID-19 waves, older males (>45 years) with comorbidities like HTN and DM were most susceptible for COVID-19 related mortality. The study also demonstrated that most of the baseline demographic and clinical characteristics which are attributed to the mortality were more common during the second wave of COVID-19.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialCTRI/2020/08/027169Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Appropriate ethical approval was obtained from the institutional ethical committee, AIIMS, Rishikesh, India before accessing the desired data.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAfter obtaining approval from corresponding author, de-identified data can be shared.